Home
About
Overview
Sharing Data
ORCID
Help
History (12)
Tcf-1 protects anti-tumor TCR-engineered CD8+ T-cells from GzmB mediated self-destruction.
Perirhinal Cortex
TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer.
Fellow
First international TNBC conference meeting report.
See All 12 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
First international TNBC conference meeting report.
First international TNBC conference meeting report. Breast Cancer Res Treat. 2018 Jun; 169(3):407-412.
View in:
PubMed
subject areas
Animals
Biomarkers, Tumor
Delivery of Health Care
Female
Healthcare Disparities
Humans
Molecular Targeted Therapy
Risk Factors
Triple Negative Breast Neoplasms
authors with profiles
Rita Nanda